Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
CNY4.98
+0.16 (+3.32%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 72 Hongxing Street
Hulin, CN
Hulin, CN
CEO
Jiujiang Yan
Website
zbdzy.com
IPO
2015-04-24
ISIN CNE100002219
Description
Heilongjiang ZBD Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the entire lifecycle of Traditional Chinese Medicine (TCM), from research and development to manufacturing and sales, exclusively within China. Its extensive product portfolio addresses a wide spectrum of health concerns, including conditions related to cardiovascular and cerebrovascular health, respiratory ailments, orthopedic issues, oncology, digestive disorders, anti-infective treatments, neuropsychiatric conditions, and genitourinary problems, among others. Established in 1996, the company maintains its headquarters in Hulin, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY4.98
+0.16 (+3.32%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
22M
Beta
0.24
Float Shares
296.60M
Free Float %
31.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.12% | -6.66% | +0.99% | -10.85% | -31.38% | -19.93% | -37.77% | -58.72% | -61.58% | -67.53% | -57.92% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
4.98
DCF (Unlevered)
3.35
-32.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.91
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-70.5% Q1'26: -61.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-410.9% Q1'26: -337.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-121.7% Q1'26: +28.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-186.5% Q1'26: -107.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-19.7% Q1'26: -7.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.04× Q1'26: -2.60× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.07B
est: 1.82B (+14.1%)
|
2.39B
est: 2.08B (+15.2%)
|
3.14B
est: 2.40B (+30.5%)
|
2.78B
est: 1.82B (+53.0%)
|
3.29B
est: 2.08B (+58.5%)
|
3.40B
est: 2.40B (+41.6%)
|
4.13B
est: 4.05B (+1.9%)
|
4.21B
est: 4.95B (-14.8%)
|
3.14B
est: 6.27B (-49.9%)
|
2.70B
est: 3.06B (-11.5%)
|
798.06M
est: 3.78B (-78.9%)
|
4.48B
4.48B – 4.48B
+18.5% YoY
|
| EBITDA |
823.30M
est: 253.66M (+224.6%)
|
609.58M
est: 289.84M (+110.3%)
|
736.52M
est: 335.56M (+119.5%)
|
749.43M
est: 253.66M (+195.4%)
|
704.85M
est: 289.84M (+143.2%)
|
741.23M
est: 335.56M (+120.9%)
|
405.93M
est: 565.29M (-28.2%)
|
-59.75M
est: 690.73M (-108.7%)
|
364.32M
est: 875.00M (-58.4%)
|
756.94M
est: -317.59M (+338.3%)
|
-1.31B
est: -392.95M (-234.3%)
|
-465.72M
-465.72M – -465.72M
-18.5% YoY
|
| EBIT |
708.11M
est: 170.14M (+316.2%)
|
463.60M
est: 194.40M (+138.5%)
|
618.46M
est: 225.07M (+174.8%)
|
627.02M
est: 170.14M (+268.5%)
|
566.43M
est: 194.40M (+191.4%)
|
585.35M
est: 225.07M (+160.1%)
|
270.38M
est: 379.15M (-28.7%)
|
-216.71M
est: 463.29M (-146.8%)
|
185.52M
est: 586.88M (-68.4%)
|
602.90M
est: -430.03M (+240.2%)
|
-1.49B
est: -532.09M (-179.7%)
|
-630.62M
-630.62M – -630.62M
-18.5% YoY
|
| Net Income |
585.31M
est: 635.89M (-8.0%)
|
509.56M
est: 772.66M (-34.1%)
|
520.87M
est: 916.01M (-43.1%)
|
462.44M
est: 635.89M (-27.3%)
|
408.65M
est: 772.66M (-47.1%)
|
436.29M
est: 916.01M (-52.4%)
|
332.10M
est: 620.38M (-46.5%)
|
185.44M
est: 225.59M (-17.8%)
|
472.74M
est: 610.98M (-22.6%)
|
438.22M
est: 488.72M (-10.3%)
|
-1.37B
est: 610.90M (-323.7%)
|
751.87M
751.87M – 751.87M
+23.1% YoY
|
| SGA |
832.16M
est: 465.95M (+78.6%)
|
975.59M
est: 532.41M (+83.2%)
|
949.10M
est: 616.39M (+54.0%)
|
1.21B
est: 465.95M (+159.4%)
|
1.18B
est: 532.41M (+121.3%)
|
1.05B
est: 616.39M (+70.9%)
|
952.16M
est: 1.04B (-8.3%)
|
915.17M
est: 1.27B (-27.9%)
|
979.01M
est: 1.61B (-39.1%)
|
575.22M
est: 736.09M (-21.9%)
|
185.25M
est: 910.77M (-79.7%)
|
1.08B
1.08B – 1.08B
+18.5% YoY
|
| EPS |
0.76
est: 0.68 (+12.3%)
|
0.60
est: 0.82 (-27.0%)
|
0.61
est: 0.97 (-37.1%)
|
0.54
est: 0.68 (-19.5%)
|
0.48
est: 0.82 (-41.6%)
|
0.51
est: 0.97 (-47.3%)
|
0.38
est: 0.66 (-41.8%)
|
0.20
est: 0.24 (-17.9%)
|
0.50
est: 0.65 (-22.6%)
|
0.47
est: 0.52 (-10.3%)
|
-1.45
est: 0.65 (-323.1%)
|
0.80
0.80 – 0.80
+23.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-131.16M
OE per share TTM
-0.14
Owner's Yield
-1.95%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
47.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 71.0K | 0.39% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 16.9K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.5K | 0.48% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 49.6K | 0.29% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 832.9K | 0.06% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 42.8K | 0.28% |
| 7 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.00% | 7.7K | 0.04% |
| 8 | Vanguard FTSE All-World ex-US ETF VEU | 0.00% | 164.8K | 0.04% |
| 9 | Vanguard Total International Stock ETF VXUS | 0.00% | 860.1K | 0.05% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 8.6K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-584.8K
Shares Outstanding
940.86M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ji Lang | Investor Relations Director | — | — |
| Jiujiang Yan | GM & Chairman | — | male |
| Lei Wang | Chief Financial Officer & Accounting Supervisor | — | male |
| Tianzhu Li | Deputy General Manager | — | female |
| Xiuzhen Li | Deputy General Manager | — | female |
| Zhongfang Zhang | Board Secretary | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603567.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
